Gemcitabine trials for Pancreatic Ductal Adenocarcinoma (PDAC)

All Gemcitabine trials · All Pancreatic Ductal Adenocarcinoma (PDAC) trials

Phase breakdown

Recruiting trials studying Gemcitabine for Pancreatic Ductal Adenocarcinoma (PDAC)

• A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
  NCT07255404 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
  NCT07223047 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07491445 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations

Common questions

How many trials study Gemcitabine for Pancreatic Ductal Adenocarcinoma (PDAC)?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.